E SYMPOSIUM **DV**



Scientific Programme





Publisher of this document & event organiser

European Academy of Dermatology & Venereology (EADV)

Via S. Balestra 22B, 6900 Lugano - Switzerland

Corporate website: eadv.org

Symposium venue

Prague Congress Centre

5. kvetna 1640/65, Nusle, 140 21 Prague 4 - CZ Official booking platform: <u>c-in.eu/eadv-hotels</u>

Website: <u>praguecc.cz</u>

Destination management company

C-IN

Contacts: hotels.eadv2025@c-in.eu

Further about the EADV Symposium

eadv.org/symposium

Follow the EADV social media channels for news and updates!








LinkedIn





Join the conversation using **#EADVSymposium**





Table of contents

Welcome from the EADV President	4
Welcome from the EADV Scientific Programming Committee	5
The Academy	6
Continuing Medical Education – Continuing Professional Development (CME-CPD)	8
Abstract reviewers	9
Scientific Programme	10
Session formats	10
Thursday 22 May 2025	11
Friday 23 May 2025	17
Saturday 24 May 2025	24
Venue floor plans	30
General information	32
Internet access / Wi-Fi	32
Onsite facilities and opening hours	32
First aid and emergency numbers	32
Official language	33
Scientific sessions	33
Certificates and accreditation	34
Abstract and ePoster	34
Information for speakers	34
Privacy	35
Virtual platform and mobile app	36
Registration	37
EADV Symposium Ticket	37
Networking Symposium	38
Healthcare Professional information and definition	39
Exhibition and Industry Sessions	40
Exhibition	41
Industry sessions	41
Participating companies	42





Welcome from the EADV President

Dear Colleagues, Dear Friends,

As President of the EADV, I am honoured to welcome you to the European Academy of Dermatology and Venereology (EADV) Spring Symposium, taking place in Prague from May 22nd – 24th 2025.



Spring Symposia hold a special place in the EADV calendar, emphasizing our continued commitment to European inclusiveness and allowing for an in-depth exploration of specific topics. For this much-anticipated event, we've chosen the Bohemian backdrop of Prague.

In Prague participants can expect to explore a rich programme curated by the Scientific Programming Committee with scientific content specifically focussing on viral infections and on new targeted treatments for inflammatory diseases. Moreover, "What's new" sessions will cover the latest updates in the main fields of dermatology and venereology, such as skin cancer, psoriasis, STIs, hidradenitis suppurativa and lupus.

This year an increased number of "interactive clinical cases" sessions will offer a greater opportunity for the audience to actively participate to the delivery of the scientific content. "Free Communications" sessions will present the best valued abstracts from a vast number of submissions.

The anticipated Plenary lecture will be delivered by Professor Bohdan Pomahac, from Yale University who will intrigue us with the 'many faces' of full-face transplantation.

You are warmly invited to join us in the city of a Hundred Spires, where the union of knowledge and participation will create an unforgettable experience.

Uvidíme se v Praze!

Prof. Branka Marinović EADV President

Brancha Glanhous





Welcome from the EADV Scientific Programming Committee

Dear Collegues and Friends

On behalf of the Scientific Programming Committee, I am delighted to welcome you to the 2025 EADV Spring Symposium in Prague, Czech Republic.



We have crafted an exciting program that covers a vast array of clinical topics. With over 25 educational sessions and more than 100 thought-provoking talks spread across three specialized tracks, there is something for everyone!

One of the highlights of the symposium is the Plenary Lecture by Professor Bohdan Pomahac from Yale University. Professor Pomahac is renowned for performing the first full-face transplants. His talk, "The Many Faces of Full-Face Transplantation," promises to be a fascinating and unmissable lecture that will set the stage for an incredible event.

Here is what you can look forward to:

Track one will feature "Focus on" sessions providing a one-day deep-dive into two timely topics of great interest: "New targeted treatments" and "Viral infections".

Track two will feature "what's new" sessions, which will allow you to stay ahead of the curve with the latest updates on melanoma, hidradenitis suppurativa, psoriasis and lupus erythematosus and more! Plus, do not miss the joint session with IUSTI for a comprehensive update on STIs.

Track three will be dedicated to interactive sessions, a crowds-favorite of our Spring Symposia! Test your diagnostic and management skills with case-based quizzes in dermoscopy, hair, nail, aesthetics and pediatrics. Back by popular demand, we will also feature challenging case presentations from residents to faculty, offering an unparallelled opportunity to refine your clinical reasoning and problem-solving skills.

And that is not all! The best-rated abstracts will take centre-stage during the Free Communications session, where presenters will showcase their latest findings and breakthroughs.

I hope to see you all in Prague for this unforgettable Symposium!

Michel Gilliet

Chair of the Scientific Programming Committee, EADV

Scientific Programming Committee:

Michel Gilliet, Jo Lambert, Paola Pasquali, Lidia Rudnicka, Eli Sprecher, Thrasyvoulos Tzellos





The Academy



EADV is committed to building the international community that develops, shares, and adopts best practices within dermatology and venereology.

With over 11'000 members and an active community of more than 17'000 professionals around the world, our goal is to be the trusted source for proven scientific advancements and practices in the prevention, diagnosis, and treatment of skin and venereal diseases.

Skin and venereal diseases are continuously evolving, as are the science and practices for preventing, diagnosing, and treating them. Advancements are being made every day that have the potential to have a significant impact on the ongoing battle to improve skin and sexual health around the world. Enabling these advancements to be validated and ensuring all professionals adopt the best practices ultimately moves dermatology and venereology forward.

EADV and its international community of passionate professionals define and spread best practices in dermatology and venereology for the benefit of all. We are a true platform for collaboration and progress across borders and sub-specialties.

Expert task forces shape standards and develop best practice guidelines, while our events, publications, and educational courses share them with our members and the broader community so they can adopt them for maximum impact.

Our values



COLLABORATIVE

We believe in working together, capitalising on one another's knowledge and expertise for the benefit of all.



PROGRESSIVIVE

We are always looking to improve, encouraging each other to change the way things are done for the better.



INCLUSIVE

We maintain that everybody has something to contribute, involving as many people as possible to maximise impact.



TRUSTED

We are professional, only sharing scientifically sound advancements so our members can move forward with confidence.





Our activities

Our activities provide a unique platform to empower members to develop, spread and adopt best practices.

EA CONGRESS

Our flagship annual event showcases the latest science, research and best practices from all areas of dermato-venereology, with networking opportunities with colleagues from around the world.

E SYMPOSIUM

Annual event focused on exploring the latest developments within specific areas of dermato-venereology, with networking opportunities with colleagues specialising in those areas.

EA JEADV

Leading international peerreviewed journal with globally recognised editorial board. Includes guidelines, reviews, clinical trials and original scientific articles.



Open access peer-reviewed journal with cutting-edge clinical content of a more practical and hands-on nature.



Extensive range of face-toface and online courses, offering continuous medical education, including a CME accredited programme, for trainees and practicing dermato-venereologists.

EA GUIDELINES

Over 30 task forces, open to all members, focusing on the creation and spreading of best practice guidelines for the prevention, diagnosis and treatment of skin and venereal diseases.



Quarterly update on what is happening within our community, and in the field of dermato-venereology around the world, with particular emphasis on the latest best practices.

EA FUNDING

A range of activities and opportunities for community members to get involved or participate in, including scholarships, grants, research funding and fellowships in prestigious hospitals.





Continuing Medical Education – Continuing Professional Development (CME-CPD)

The EADV Symposium 2025, Prague, 22/05/2025 - 24/05/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14.5 European CME credits (ECMEC®s).

CME credits

Each medical specialist can claim only those hours of credit actually spent in the educational activity (as recorded by the scanning process or online access). Here below please find the breakdown of credits per day:

Thursday, 22 May 2025	4 credits	The accreditation system is based on 1 ECMEC per hour.
Friday, 23 May 2025	6 credits	No credits will be provided by the EADV to
Saturday, 24 May 2025	4.5 credits	delegates participating in sessions organised by industry

Procedure to gain your credits

Scan your badge, complete the evaluation forms and download the CME-CPD Certificate.

The EADV offers individual CME-CPD participation through the scanning of the bar code and the speaker/session evaluation that will be available <u>until Sunday</u>, 31 August 2025.

- 1. **Scan your badge** as you pass through the entrance of each session hall, your data will be then transmitted to the system (or access the online session on-demand).
- 2. **Complete the anonymous online evaluation** for each attended session. Access the evaluation system in the "My Area" section on the <u>online Symposium platform</u>.
- 3. Download your CME-CPD certificate and retain it for your personal records.

Evaluation data is essential to our statistics and is of considerable help in the choice of future topics and speakers. Your feedback and comments are greatly appreciated.

Conversion of Credits

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Information regarding the conversion of EACCME® credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.





Abstract reviewers

EADV is grateful to the following reviewers who have given their time and expertise in reviewing the submitted abstracts:

Ashraf Badawi Kateryna Kolyadenko

Zsuzsanna Bata-Csorgo Dimitra Koumaki

Johann Bauer Aikaterini Liakou

Aslı Bilgic Arjen Fokko Nikkels

Jose-Manuel Carrascosa Rodica Olteanu

Pavel Chernyshov David Pesqué

Zsanett Renáta Csoma Sandra Peternel

Robert Artur Dahmen Asja Prohić

Clio Dessinioti Adam Reich

Dario Didona Mihael Skerlev

Nejib Doss Dusan Skiljevic

Kossara Drenovska Pietro Sollena

Andrew Y. Finlay Efthymia Soura

Klaus Fritz Sundaramoorthy Srinivasan

Carlo Gelmetti Kaisa Tasanen-Maatta

Jürg Hafner Tiago Torres

Claudia Heller-Vitouch Stefano Veraldi

Alexander Katoulis Christian Vestergaard

Jana Kazandjieva Torsten Zuberbier





Scientific Programme

The scientific programme is organised on full or half-day tracks; each track has a specific topic and a structured programme.

Session formats

Sessions of different formats will cover the important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives. The following session types will be scheduled throughout the duration of the Symposium and are available to all registered participants.

- Plenary sessions: Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.
- **Focus on:** These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology / epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.
- What's new: These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.
- Interactive clinical cases: These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics. The topic of each presentation should be developed from clinical cases and include clinical photographs. The main objective is to provide the audience clues for differential diagnosis and disease management in their daily practice. Each presentation is supposed to be interactive, with multiple-choice question made to the audience in accordance with the subjects treated in the talks. Each speaker will be asked to include 2-3 questions by "data" along with the different answers' options.
- Free communications: Authors of the most highly-ranked abstracts assessed by a selected panel of abstract reviewers are invited to a provide a 10-minute oral presentation.





Programme at a glance

	FORUM HALL	SOUTH HALL 2	SOUTH HALL 1
14:00 15:30	Melanoma	Focus on new targeted treatment: Inflammatory diseases	Free communications 1
15:45 17:15	Keratinocytic skin cancer	Focus on new targeted treatment: Inflammatory diseases	Free communications 2
17:30 18:30	Plenary session with keynote lecture		





DITI.I		Melanoma Chairs: Ana-Maria Forsea (Bucharest, Romania) Eduardo Nagore (Valencia, Spain)
DITI.IA	14:00	Impact of prevention campains Ana-Maria Forsea (Bucharest, Romania)
DITI.1B	14:20	Novel imaging techniques Mariano Suppa (Brussels, Belgium)
DITI.IC	14:40	Management of lentigo maligna Eduardo Nagore (Valencia, Spain)
DITI.ID	15:00	Adjuvant, neoadjuvant treatment and beyond Petr Arenberger (Prague, Czech Republic)
DITI.IE	15:20	Discussion, Q&A

WHAT'S NEW ▼ 15:45 – 17:15 CEST FORUM HALL

DIT1.2		Keratinocytic skin cancer Chairs: Yolanda Gilaberte Calzada (Zaragoza, Spain), Alexander Stratigos (Athens, Greece)
DITI.2A	15:45	Sunscreens and chemoprevention Yolanda Gilaberte Calzada (Zaragoza, Spain)
DITI.2B	16:05	Non-surgical therapies Alessandro Di Stefani (Rome, Italy)
DIT1.2C	16:25	Identification of high risk tumours Alexander Stratigos (Athens, Greece)
DITI.2D	16:45	Medical treatment of advanced tumours Ariadna Ortiz (Toulouse, France)
DITI.2E	17:05	Discussion, Q&A





D1T2.1		Focus on new targeted treatment: Inflammatory diseases Chairs: Patrick Brunner (New York, United States) Claudia Günther (Dresden, Germany)
DIT2.1A	14:00	Oral IL-23 and IL-17 inhibitors Tiago Torres (Porto, Portugal)
DIT2.1B	14:20	New Th2-targeting drugs Patrick Brunner (New York, United States)
DIT2.1C	14:40	Are JAK-inhibitors the answer for alopecia areata and vitiligo? Brett King (Fairfield, United States)
DIT2.1D	15:00	New interferon and plasmacytoid dendritic cells targeted treatments for autoimmune diseases Claudia Günther (Dresden, Germany)
DIT2.1E	15:20	Discussion, Q&A

	1	
D1T2.2		Focus on new targeted treatment: Inflammatory diseases Chairs: Jacek Szepietowski (Wroclaw, Poland) Torsten Zuberbier (Berlin, Germany)
DIT2.2A	15:45	New drugs for autoinflammatory/pustular/neutrophilic diseases Miloslav Salavec (Hradec Králové 5, Czech Republic)
DIT2.2B	16:05	New central and peripheral itch drugs Jacek Szepietowski (Wroclaw, Poland)
DIT2.2C	16:25	New drugs for urticaria Torsten Zuberbier (Berlin, Germany)
DIT2.2D	16:45	B-cell-targeted treatments for bullous diseases Frederic Caux (Bobigny, France)
DIT2.2E	17:05	Discussion, Q&A





FREE COMMUNICATIONS \$\overline{\mathbb{X}}\$ 14:00 – 15:30 CEST \$\overline{\mathbb{O}}\$ SOUTH HALL 1

FC.1		Free communications 1 Chairs: Catherine van Montfrans (Rotterdam, Netherlands) Jo LW Lambert (Ghent, Belgium)
FC1.1A	14:00	Al-Generated Dermatological Images: A Data-Efficient Model Training Strategy in a Novel Frontier Ayberk Aktaran (Istanbul, Türkiye)
FC1.1B	14:10	Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Relapsed/Refractory IIB/IVB Mycosis Fungoides / Sézary Syndrome Patients after Previous Systemic Treatment. EORTC-1652-CLTG "PARCT" Gabriele Roccuzzo (Torino, Italy)
FC1.1C	14:20	Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid: Results From LIBERTY-BP ADEPT Phase 2/3 Study Frederic Caux (Bobigny, France)
FC1.1D	14:30	Characterizing Unique Clinical and Serologic Phenotypes of Classic and Immune Checkpoint Inhibitor Induced Bullous Pemphigoid Aaron Mangold (Scottsdale, United States)
FC1.1E	14:40	Investigating the Role of Basal KC1 Keratinocytes and CXCL13+CD8+ T Cells on the Rapid Efficacy of Baricitinib in Treating Lichen Planus Aaron Mangold (Scottsdale, United States)
FC1.1F	14:50	Investigating melanogenesis-related microRNAs as disease biomarkers in vitiligo Noha Tawfik (ismailia, Egypt)
FC1.1G	15:00	six-month clinical outcomes of omalizumab treatment in bullous pemphigoid:a retrospective study Çağrı Enes Yılmaz (Edirne, Türkiye)
FC1.1H	15:10	Long-term experience with Afamelanotide in patients affected by Erythropoietic protoporphyria Luca Barbieri (Rome, Italy)
FC1.1I	15:20	Ruxolitinib versus Roflumilast: A Meta-analysis of the Comparative Efficacy of Two Topical Therapies for Atopic Dermatitis Grace Xiong (Hamilton, Canada)





FREE COMMUNICATIONS	FREE COMMUNICATIONS	▲ 15:45 – 17:15 CEST	SOUTH HALL 1
---------------------	---------------------	----------------------	--------------

FC.2		Free communications 2 Chairs: Nicole Jeanne Jouan (Brest, France) Menno de Rie (Breukelen, Netherlands)
FC2.1A	15:45	Gene-Expression Signatures and Prognosis in Intermediate to High- Risk Cutaneous Squamous Cell Carcinoma Aaron Mangold (Scottsdale, United States)
FC2.1B	15:55	Interpretable Self-Supervised AI for cSCC: Addressing Inter-Clinician Variability in Tumor Grading and Enhancing Metastasis Prediction Aaron Mangold (Scottsdale, United States)
FC2.1C	16:05	In-vivo and ex-vivo sonographic evaluation of tumor margins during micrographic controlled surgery: a promising new tool in dermato-oncology? Diana Crisan (Ulm, Germany)
FC2.1D	16:15	B-cell and T-cell cytofluorimetric repertoire characterize clinical response to Rituximab in Pemphigus vulgaris patients: long-term remission vs relapse Simone Liguori (Naples, Italy)
FC2.1E	16:25	Ireland's first confirmed case of Trichophyton indotineae and response to topical Griseofulvin Emma Carroll (Dublin, Ireland)
FC2.1F	16:35	First Cases of Trichophyton mentagrophytes ITS Genotype VII (TMVII) in the Czech Republic: Emerging Sexually Transmitted Dermatophyte Infections Anna Engelmann (Prague, Czech Republic)
FC2.1G	16:45	Real world effects of dupilumab on prurigo nodularis patients Hana Elhassan (Edinburgh, United Kingdom)
FC2.1H	16:55	Remission maintenance with conventional immunosuppressants in Pemphigus vulgaris treated with Rituximab: a multicenter retrospective study Simone Liguori (Naples, Italy)
FC2.1I	17:05	Distinct MRGPRX2-Mediated Mast Cell Activation in Chronic Pruritus of Unknown Origin Compared to IgE-mediated Atopic Dermatitis Mr. Yagiz Matthew Akiska (Washington, United States)





PLENARY SESSION ▼ 17:30 – 18:30 CEST ▼ FORUM HALL

PL	17:30 - 18:30	Plenary session Chairs: Michel Gilliet (Lausanne, Switzerland) Branka Marinovic (Zagreb, Croatia)
PLIA	17:30	Welcome from the EADV President Branka Marinovic (Zagreb, Croatia)
PLIB	17:40	Welcome Jana Tresnak Hercogova (Prague, Czech Republic)
PLIC	17:48	Welcome Petr Arenberger (Prague, Czech Republic)
PLID	17:55	Keynote speaker introduction Michel Gilliet (Lausanne, Switzerland)
PLIE	18:00	The many faces of full face transplantation Bohdan Pomahac (New Haven, United States)





Programme at a glance

	FORUM HALL	SOUTH HALL 2	SOUTH HALL 1
09:00 10:00	Adverse anti-cancer drug reactions	Dermoscopy	Focus on new targeted treatment: New technologies
10:45 12:15	Hidradenitis suppurativa	Clinical-pathological correlations	Focus on new targeted treatment: Skin cancer
12:45 13:45	Industry Sessions		
14:00 15:30	Emergencies in dermatology	Hair and nail disorders	Focus on viral infections: Emerging threats
15:45 17:15	Regenerative medicine and aesthetics	The hot seat: Local residents quiz the international faculty	Focus on viral infections: Onco-viruses and herpes viruses





WHAT'S NEW ▼ 69:00 – 10:30 CEST ▼ FORUM HALL

D2T1.1		Adverse anti-cancer drug reactions Chairs: Maria Inês Coutinho (Coimbra, Portugal) Lukas Flatz (Tübingen, Germany)
D2T1.1A	09:00	Immune checkpoint inhibitors-related reactions Lukas Flatz (Tübingen, Germany)
D2T1.1B	09:20	Targeted therapies-related reactions Rolland Gyulai (Szeged, Hungary)
D2T1.1C	09:40	Chemotherapy-related reactions Barbara Meier-Schiesser (Zurich, Switzerland)
D2T1.1D	10:00	Management: To stop or not to stop the anti-cancer treatment Maria Inês Coutinho (Coimbra, Portugal)
D2T1.1E	10:20	Discussion, Q&A

WHAT'S NEW ▼ 10:45 – 12:15 CEST FORUM HALL

D2T1.2		Hidradenitis suppurativa Chairs: Francesca Prignano (Florence, Italy) Christos C. Zouboulis (Dessau, Germany)
D2T1.2A	10:45	Pathophysiology and endotypes Francesca Prignano (Florence, Italy)
D2T1.2B	11:05	Clinical outcomes of importance Thrasyvoulos Tzellos (Bodø, Norway)
D2T1.2C	11:25	Imaging-guided surgery Alessandra Michelucci (Pisa, Italy)
D2T1.2D	11:45	Biologics and small molecules Christos C. Zouboulis (Dessau, Germany)
D2T1.2E	12:05	Discussion, Q&A





WHAT'S NEW ▼ 14:00 – 15:30 CEST ▼ FORUM HALL

D2T1.3		Emergencies in dermatology Chairs: Carmen Maria Salavastru (Bucharest, Romania) Jana Tresnak Hercogova (Prague, Czech Republic)
D2T1.3A	14:00	Severe drug reactions Wolfram Hoetzenecker (Linz, Austria)
D2T1.3B	14:20	Neonatal life-threatening conditions Carmen Maria Salavastru (Bucharest, Romania)
D2T1.3C	14:40	Severe bacterial infections Jana Tresnak Hercogova (Prague, Czech Republic)
D2T1.3D	15:00	Erythroderma Alina Jankowska-Konsur (Wroclaw, Poland)
D2T1.3E	15:20	Discussion, Q&A

WHAT'S NEW ▼ 15:45 – 17:15 CEST FORUM HALL

D2T1.4		Regenerative medicine and aesthetics Chairs: Brunilda Bardhi (Tirana, Albania) Beata Bergler-Czop (Katowice, Poland)
D2T1.4A	15:45	Metformin for anti-ageing Aseem Sharma (Mumbai, India)
D2T1.4B	16:05	Adipose derived stem cells and PRP Peter Kicko (Prague, Czech Republic)
D2T1.4C	16:25	The role of hormones in ageing Beata Bergler-Czop (Katowice, Poland)
D2T1.4D	16:45	Danger of cosmetic procedures in the young Brunilda Bardhi (Tirana, Albania)
D2T1.4E	17:05	Discussion, Q&A





INTERACTIVE CLINICAL CASES

▼ 09:00 – 10:30 CEST

SOUTH HALL 2

D2T2.1		Dermoscopy Chairs: Caterina Longo (Modena, Italy) Monika Arenbergerova (Prague, Czech Republic)
D2T2.1A	09:00	Pink / Red Caterina Longo (Modena, Italy)
D2T2.1B	09:20	Blue / Violet Pedro Zaballos (Taragona, Spain)
D2T2.1C	09:40	Yellow / Orange Ofer Reiter Agar (Petah Tikvah, Israel)
D2T2.1D	10:00	Brown / Black Monika Arenbergerova (Prague, Czech Republic)
D2T2.1E	10:20	Discussion, Q&A

INTERACTIVE CLINICAL CASES

▼ 10:45 – 12:15 CEST

SOUTH HALL 2

D2T2.2		Clinical-pathological correlations Chairs: Franco Rongioletti (Milan, Italy) Mahtab Samimi (Tours, France)
D2T2.2A	10:45	Inflammatory diseases Kristina Semkova (London, United Kingdom)
D2T2.2B	11:05	Tumours Laurence Feldmeyer (Bern, Switzerland)
D2T2.2C	11:25	Infections and infestations Franco Rongioletti (Milan, Italy)
D2T2.2D	11:45	Mucous membranes Mahtab Samimi (Tours, France)
D2T2.2E	12:05	Discussion, Q&A





INTERACTIVE CLINICAL CASES

▼ 14:00 – 15:30 CEST

SOUTH HALL 2

D2T2.3		Hair and nail disorders Chairs: Matilde Iorizzo (Lugano, Switzerland) Alexander Katoulis (Athens, Greece)
D2T2.3A	14:00	Scarring alopecia Matilde Iorizzo (Lugano, Switzerland)
D2T2.3B	14:20	Non-scarring alopecia Anastasia Therianou (London, United Kingdom)
D2T2.3C	14:40	Hair and nail disorders in systemic diseases Alexander Katoulis (Athens, Greece)
D2T2.3D	15:00	Dystrophic nails Marcel Pasch (Nijmegen, Netherlands)
D2T2.3E	15:20	Discussion, Q&A

INTERACTIVE CLINICAL CASES

▼ 15:45 – 17:15 CEST

SOUTH HALL 2

D2T2.4		The hot seat: Local residents quiz the international faculty Chair: Antonio Torrelo (Madrid, Spain) Faculty: Markus Vincent Starink (Amstelveen, Netherlands) Christos C. Zouboulis (Dessau, Germany) Jo LW Lambert (Ghent, Belgium)
D2T2.4A	15:45	Case 1: White macules Zuzana Kondasova (Prague, Czech Republic)
D2T2.4B	16:05	Case 2: Ulcers Filip Skokan (Brno, Czech Republic)
D2T2.4C	16:25	Case 3: Pimple Natalie Rafcikova (Prague, Czech Republic)
D2T2.4D	16:45	Case 4: Erythoderma Amir Samadian (Brno 2, Czech Republic)
D2T2.4E	17:05	Discussion, Q&A





FOCUS ON	▼ 09:00 – 10:30 CEST	SOUTH HALL 1
1 0 0 0 0 1 1	= 03:00 10:50 CE31	V SOUTH TIMEE I

D2T3.1		Focus on new targeted treatment: New technologies Chairs: Johann Bauer (Salzburg, Austria) Su Lwin (London, United Kingdom)
D2T3.1A	09:00	Novel drug technologies Kristian Reich (Hamburg, Germany)
D2T3.1B	09:20	Cell therapy Su Lwin (London, United Kingdom)
D2T3.1C	09:40	Targeted topicals Christoph Schlapbach (Bern, Switzerland)
D2T3.1D	10:00	Gene therapy Johann Bauer (Salzburg, Austria)
D2T3.1E	10:20	Discussion, Q&A

FOCUS ON		▼ 10:45 – 12:15 CEST	SOUTH HALL 1
D2T3.2		Focus on new targeted treatment: Skin cancer Chairs: Dirk Schadendorf (Essen, Germany) Reinhard Dummer (Zürich, Switzerland)	
D2T3.2A 10	0:45	Preventive and therapeutic vaccines Teresa Amaral (Tübingen, Germany)	
D2T3.2B 11:	1:05	New checkpoint inhibitors Marek Pásek (Prague, Czech Republic)	
D2T3.2C 11:	1:25	Cell-based therapy in melanoma Reinhard Dummer (Zürich, Switzerland)	
D2T3.2D 11:	1:45	Small molecule inhibitors Dirk Schadendorf (Essen, Germany)	
D2T3.2E 12:	2:05	Discussion, Q&A	





D2T3.3		Focus on viral infections: Emerging threats Chair: John Trinidad (Boston, United States) Arjen Fokko Nikkels (Liege, Belgium)
D2T3.3A	14:00	New problems with old viruses? Roman Prymula (Hradec Kralove, Czech Republic)
D2T3.3B	14:20	Tropical viral infections Arjen Fokko Nikkels (Liege, Belgium
D2T3.3C	14:40	M-Pox John Trinidad (Boston, United States)
D2T3.3D	15:00	HIV in the PREP era Katharina Grabmeier-Pfistershammer (Vienna, Austria)
D2T3.3E	15:20	Discussion, Q&A

D2T3.4		Focus on viral infections: Onco-viruses and Herpes viruses Chairs: Peter Greenhouse (Bristol, United Kingdom) Georg Stary (Vienna, Austria)
D2T3.4A	15:45	HPV Peter Greenhouse (Bristol, United Kingdom)
D2T3.4B	16:05	EBV and cutaneous lymphomas Pablo Luis Ortiz Romero (Madrid, Spain)
D2T3.4C	16:25	Kaposi sarcoma Stephan Grabbe (Mainz, Germany)
D2T3.4D	16:45	Herpes infections Georg Stary (Vienna, Austria)
D2T3.4E	17:05	Discussion, Q&A





Programme at a glance

	FORUM HALL	SOUTH HALL 2	SOUTH HALL 1
09:00 10:00	Hair and Nails	Psoriasis	Focus on viral infections: Viruses and exanthema
10:45 12:15	Aesthetic dermatology	Genodermatoses	Focus on viral infections: Viruses and drugs
12:30 14:00	Paediatric dermatology	Joint EADV-IUSTI-EU session on venereology	Connective tissue diseases





INTERACTIVE CLINICAL CASES ▼ 09:00 – 10:30 CEST ▼ FORUM HALL

D3T1.1		Hair and Nails Chairs: Lidia Rudnicka (Warsaw, Poland) Francesca Pampaloni (Bologna, Italy)
D3T1.1A	09:00	Hair loss Lidia Rudnicka (Warsaw, Poland)
D3T1.1B	09:20	Scalp diseases Juan Jimenez Cauhe (Madrid, Spain)
D3T1.1C	09:40	Nail tumors Miroslav Důra (Prague, Czech Republic)
D3T1.1D	10:00	Inflammatory nail diseases Francesca Pampaloni (Bologna, Italy)
D3T1.1E	10:20	Discussion, Q&A

INTERACTIVE CLINICAL CASES ▼ 10:45 – 12:15 CEST ▼ FORUM HALL

D3T1.2		Aesthetic dermatology Chairs: Daniela Hartmann (Munich, Germany) Severin Läuchli (Zurich, Switzerland)
D3T1.2A	10:45	Anti-aging Brunilda Bardhi (Tirana, Albania)
D3T1.2B	11:05	Pigmentation Daniela Hartmann (Munich, Germany)
D3T1.2C	11:25	Tattoos Isabelle Rooms (Bruges, Belgium)
D3T1.2D	11:45	Scars Severin Läuchli (Zurich, Switzerland)
D3T1.2E	12:05	Discussion, Q&A





D3T1.3		Paediatric dermatology Chairs: Yuval Ramot (Jerusalem, Israel) Regina Fölster-Holst (Kiel, Germany)
D3T1.3A	12:30	Genodermatoses Marie-Anne Morren (Lausanne, Switzerland)
D3T1.3B	12:50	Inflammatory dermatoses Yuval Ramot (Jerusalem, Israel)
D3T1.3C	13:10	Hair disorders Regina Fölster-Holst (Kiel, Germany)
D3T1.3D	13:30	Vascular malformations Malgorzata Dominiak (Lodz, Poland)
D3T1.3E	13:50	Discussion, Q&A

WHAT'S NEW		▼ 09:00 – 10:30 CEST	SOUTH HALL 2
D3T2.1		Psoriasis Chairs: Jo LW Lambert (Ghent, Belgium) Michel Gilliet (Lausanne, Switzerland)	
D3T2.1A	09:00	Pustular psoriasis Johann Gudjonsson (Ann Arbor, United States)	
D3T2.1B	09:20	Disease modification Satveer Mahil (London, United Kingdom)	
D3T2.1C	09:40	Novel treatments Jo LW Lambert (Ghent, Belgium)	
D3T2.1D	10:00	Tailored treatment approaches Michel Gilliet (Lausanne, Switzerland)	
D3T2.1E	10:20	Discussion, Q&A	





WHAT'S NEW ▼ 10:45 - 12:15 CEST ▼ SOUTH HALL 2

D3T2.2		Genodermatoses Chairs: Eli Sprecher (Tel Aviv, Israel) Jemima Mellerio (London, United Kingdom)
D3T2.2A	10:45	Epidermal differentiation disorders Eli Sprecher (Tel Aviv, Israel)
D3T2.2B	11:05	Epidermolysis bullosa Jemima Mellerio (London, United Kingdom)
D3T2.2C	11:25	Hair disorders Alexandros Onoufriadis (Thessaloniki, Greece)
D3T2.2D	11:45	Familial cancer syndromes Emily Avitan-Hersh (Haifa, Israel)
D3T2.2E	12:05	Discussion, Q&A

WHAT'S NEW ▼ 12:30 - 14:00 CEST ▼ SOUTH HALL 2

D3T2.3		Joint EADV-IUSTI-EU Session on Venereology Chairs: Branka Marinovic (Zagreb, Croatia) George Sorin Tiplica (Bucharest, Romania)
D3T2.3A	12:30	Challenging genital dermatoses Vladimir Vasku (Brno, Czech Republic)
D3T2.3B	12:50	Early diagnosis of genital ulcers Andrew Winter (Glasgow, United Kingdom)
D3T2.3C	13:10	Non-infectious genital ulcers Electra Nicolaidou (Athens, Greece)
D3T2.3D	13:30	The dilemmas of Doxy PEP Derek Freedman (Dublin, Ireland)
D3T2.3E	13:50	Discussion, Q&A





FOCUS ON	▼ 09:00 – 10:30 CEST	SOUTH HALL 1
----------	----------------------	--------------

D3T3.1		Focus on viral infections: Viruses and exanthema Chairs: Margarida Gonçalo (Coimbra, Portugal) Branka Marinović (Zagreb, Croatia)
D3T3.1A	09:00	Exanthems: to investigate or not to investigate? Klara Martinaskova (Prešov, Slovakia)
D3T3.1B	09:20	Differential diagnosis in children Antonio Torrelo (Madrid, Spain)
D3T3.1C	09:40	Differential diagnosis in adults Margarida Gonçalo (Coimbra, Portugal)
D3T3.1D	10:00	Differential diagnosis in pregnant women Branka Marinović (Zagreb, Croatia)
D3T3.1E	10:20	Discussion, Q&A

FOCUS ON		▼ 10:45 – 12:15 CEST	SOUTH HALL 1
D3T3.2		Focus on viral infections: Viruses and drugs Chairs: Philippe Musette (Bobigny, France) Janette Baloghová (Košice, Slovakia)	
D3T3.2A	10:45	Viral reactivation and drug hypersensitivity Philippe Musette (Bobigny, France)	
D3T3.2B	11:05	Anti-virals for the dermatologist Janette Baloghová (Košice, Slovakia)	
D3T3.2C	11:25	Oncolytic therapy Lukas Flatz (Tübingen, Germany)	
D3T3.2D	11:45	Vaccination for dermatologists Jan Hugo (Praha, Czech Republic)	
D3T3.2E	12:05	Discussion, Q&A	






WHAT'S NEW ▼ 12:30 – 14:00 CEST ▼ SOUTH HALL 1


D3T3.3		Connective tissue diseases Chairs: Miloš Nikolić (Belgrade, Serbia) Aveen Connolly (London, United Kingdom)
D3T3.3A	12:30	Cutaneous lupus erythematosus Ondřej Kodet (Prague, Czech Republic)
D3T3.3B	12:50	Systemic lupus erythematosus Miloš Nikolić (Belgrade, Serbia)
D3T3.3C	13:10	Dermatomyositis Aveen Connolly (London, United Kingdom)
D3T3.3D	13:30	Localized scleroderma and systemic sclerosis Thomas Krieg (Cologne, Germany)
D3T3.3E	13:50	Discussion, Q&A






Venue floor plans













General information

Internet access / Wi-Fi

Free Wi-Fi will be available in all areas of the venue including the session and meeting rooms. Network: EADV2025 Password: EADV2025

Onsite facilities and opening hours

Venue opening hours

Thursday 22 May 10:00 – 22.00

• Friday 23 May 08:00 – 18:30

• Saturday 24 May 08:00 – 14:30

Registration area

The registration area is located on level 0 of Prague Congress Centre and will be open as follows:

Thursday 22 May 10:00 – 18.00Friday 23 May 08.00 – 16:00

Saturday 24 May 08.00 – 13:00

Speaker preview room

The speaker preview room is in the ZOOM on level 1 of Prague Congress Centre and will be open as follows:

• Thursday 22 May 10.00 – 17.30

• Friday 23 May 08.00 – 17.30

Saturday 24 May 08.00 – 13.00

Cloakroom

The cloakroom is located on level 0 of Prague Congress Centre and will be open as follows:

• Thursday 22 May 10.00 – 22.00

Friday 23 May 08.00 – 18:30

Saturday 24 May 08.00 – 14:30

Lost & found

Please hand in all found items and ask for lost items at the cloakroom.

First aid and emergency numbers

In case of need please go to the first aid room located on Level 0 of Prague Congress Centre. First Aid service is operated by Meditrans

Emergency number:

- 112
- +420 739359177

Closest hospital to Prague Congress Centre:

VFN – Všeobecná fakultní nemocnice v Praze U Nemocnice 499/2, 128 08 Nové Město (2.5km by car)

Phone number: +420 224 961 111





General information

Official language

English is the official language of the Symposium. No simultaneous translation will be provided at any EADV scientific session.

Scientific sessions

Sessions of different formats will cover the important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives. The following session types will be scheduled throughout the duration of the Symposium and are available to all registered participants: Plenary lectures, Focus on, What's new, Clinical cases discussion and Free communications.

The scientific programme has been organised on full or half-day tracks; each track has a specific topic and a structured programme. Three separate levels are offered: one junior track for Trainees and Residents, another for Board-Certified Dermatologists and Venereologists and a third one for Expert Specialists. Entry will be made on a first-come, first-served basis.



The use of mobile phones as well as audio and video recording devices are strictly prohibited within the scientific session rooms. Please ensure that you have your mobile phone switched off when attending a session. Photography is not permitted.

Session halls

All session rooms are equipped with LCD projection for PowerPoint presentation.

All Scientific Session rooms for the EADV Symposium are located within Prague Congress Centre. Please refer to the floor plans for orientation.

Seating is regulated on a first-come, first-served basis. We recommend you go to the session room well in advance of the session to ensure your place. Due to safety regulations, the organisers will close the access to the session if all seats are occupied. Delegates are not permitted to stand in the aisles of the session rooms.

Catering facilities

Lunches and coffee breaks are not included in the registration fees. Meals and snacks can be purchased within the Symposium venue during the opening hours in various catering areas of the venue. Please refer to the floor plans for orientation.





General information

Certificates and accreditation

All registered participants will be able to download their certificates online based on their level of engagement:

- A **Certificate of Attendance** is available for all registered participants who have a valid registration badge and attended at least 1 session
- A CME-CPD Certificate is available for all participants who actively attended scientific sessions, have their badge scanned and completed the online evaluation forms
- An ePoster Certificate is available for all leading ePoster authors
- An **Oral presentation Certificate** is available for all presenters of an abstract accepted for an oral presentation
- A **Speaker presentation Certificate** is available for all presenters who have delivered a lecture in a scientific session.

The certificates are not sent out automatically. They can be downloaded from our platform by entering the <u>email address and password used during the registration process</u> OR the <u>EADV member log-in details</u> (if a EADV member).

Platform URL: eadv.m-anage.com/Home/Index/Event/eadvsymposium2025/en-GB

Abstract and ePoster

Accepted abstracts will be made available on our website eadv.org/scientific/abstract-books/

Abstracts selected for ePosters will be published as electronic posters during the Symposium and will be available for viewing in the ePoster area, on level 2 of the Prague Conference Centre. 16 big screens are provided and configured exclusively to display the ePosters.

The ePosters can be viewed sequentially by number, submission topic or searched individually by title, key word, or author. The ePoster area will be open as follows:

Thursday 22 May 11.00 - 17.30
Friday 23 May 08.00 - 17.30
Saturday 24 May 08.00 - 14.30

Information for speakers

All presentations must be in English. Speakers should also verify in the Final Programme that the name of the room and time of session have not changed.

Speakers must upload their presentation <u>3 hours (minimum) before the lecture</u> if not already uploaded.

Speakers with a presentation during the first time slot of the morning are requested to upload their PowerPoint presentation the day before.





Privacy

Use of private data

The data made available through the Registration Portal for Congresses and Symposia are gathered and treated by the EADV in compliance with the Swiss regulation on data protection and the General Data Protection Regulation. We advise you to read full EADV Privacy Policy on eadv.org/privacy-policy.

Transferring the data to the industry session organiser

During the EADV Symposium you have the right to transfer the data collected by EADV to another controller ("the Industry session organiser", "Industry"). It might happen through scanning a badge, QR code or other means. Each participant shall consider that by accepting any scanning of the badge, QR code or other means at any industry session at the Symposium, the participant gives authorization to the EADV to transfer the data of the participant to the Industry.

The EADV is obliged to make this process possible but does not take any responsibility for what happens with the data after it is transferred to the Industry session organiser. We advise to make sure that Industry presents Privacy Policy and read it carefully. It may occur that purposes described by the Industry Exhibitor might include the promotion of pharmaceutical products and similar.

Transfer of the data from the EADV to exhibiting Industry does not mean the removal of original data from EADV. If you wish for the data to be removed or have any request or questions, please contact us at any time by writing to eadvoffice@eadv.org.

Third-party registration

The EADV does not officially support or authorize any third-party organization that creates registrations for individuals or groups. We strongly advise to register accordingly to official fees and only on EADV official websites.

Liability disclaimer

The Organisers cannot be held liable for any hindrance or disruption to the EADV Symposium arising from political, social or economic events or any other unforeseen incidents beyond their control. The Organisers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to Symposium participants, either during or as a result of the Symposium or during all tours and events. Registration of a participant entails acceptance of these conditions.





Virtual platform and mobile app

The EADV app will bring the EADV Symposium to your smartphone!

Stay connected and make the most of your Symposium experience with the official virtual platform and mobile app. Designed to keep you informed and engaged, it offers a seamless way to navigate the Symposium and explore everything it has to offer.

Get instant access to the full scientific programme, abstracts, ePosters, and download your certificates. Participate in session surveys, and don't miss any of the Symposium's latest news.

Even after the Symposium concludes, the platform is your go-to resource for accessing ondemand content and downloading your certificates.

- Access the full scientific programme and create your own agenda
- Access all Abstracts and ePosters
- Evaluate your sessions and gain your
 CME-CPD credits
- **Participate to the sessions** by answering the polls and ask your questions
- Download your Certificates
- Rewatch all the scientific sessions on demand when the event has concluded



SCAN TO LEARN MORE

or visit eadv.org/symposium/app/







Registration

Any person who wishes to make a registration for the EADV Symposium can proceed online (until Saturday 24 May 2025), on the registration system platform available on eadv.org/symposium/registration

Fees, deadlines, policies and other import information are published online. You can find them on the above-mentioned link.

EADV Symposium Ticket

The EADV Spring Symposium Ticket includes:

- Name badge
- Admission to EADV Scientific Sessions
- Admission to the Networking Symposium Thursday 22 May 2025 (No entertainment)
- Access to the ePoster area
- Access to Satellite Symposia Sessions *
- Possibility to collect ECMEC Credits upon participation in the EADV Scientific Sessions

A 1-Day Ticket is only valid for 1 of the 3 days of the Symposium and is limited to one ticket per participant.

Name Badge

Registered participants are invited to print out their badge at the self-printing machines on arrival to the registration area. The name badge is the official EADV Symposium identification document and should be worn at all times in order to gain entry to the various Symposium areas.

The name badge is your ticket for booked activities and sessions. Admission to other areas of the venue is not permitted without badge identification.

The badge includes a QR-code containing your full address and email. It is the participant's decision to disclose these details to the Industry Session's organisers with a scanner.

^{*} IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the industry session. The organising company reserves the right to refuse single categories if not adequately related to the objective and purpose of the session.





Networking Symposium

Join us to celebrate the start of the 2025 EADV Symposium and participate in the first plenary lecture of this year's edition.

The opening plenary lecture will be preceded by a welcome address from EADV President, Prof. Branka Marinović, who will officially kick off the 2025 EADV Symposium. Following her remarks, Prof. Bohdan Pomahac will deliver a captivating lecture on the groundbreaking field of face transplantation.

To conclude the evening, join us for a networking reception starting at 18:30 on level 2 of the Prague Congress Centre, an excellent opportunity to connect with colleagues and speakers in a relaxed setting.

Thursday, 22 May 2025

17:30

Opening plenary lecture

Forum hall – Level 2 Prague Congress Centre

18:30

Networking Reception

Level 2 Prague Congress Centre







Healthcare Professional information and definition

1. Important note to Healthcare and Non-Healthcare Professionals

Access to the different areas and sessions of the Symposium depends on Healthcare Professional status.

As a multidisciplinary audience will attend the EADV Symposium, the EADV will assign different classes to Healthcare Professionals (HCPs) and Non-Healthcare Professionals (non-HCPs) to ensure compliance with the AIFP (Asociace inovativního farmaceutického průmyslu v České republice) Code of Practice.

Please read the description below to ensure that you (or your delegates) comply with the regulations in place.

EADV members are not automatically considered Healthcare Professionals. Please select the correct status (HCP or non-HCP) during registration.

2. **Definition**

The AIFP code defines Healthcare Professionals as follows:

"any natural person that is a member of the medical, dental, pharmacy, or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product and whose primary practice, principal professional address or place of incorporation is in Europe.

For the purpose of AIFP Code, the definition of HCPs includes: any official or state employee, agency or other organization (whether in the public or private sector) that may prescribe, purchase, supply, recommend or administer Medicinal Products and any employee of a Member Company whose primary occupation is that of a practicing HCP, but excludes all other employees of a Member Company and a wholesaler or distributor of Medicinal Products."

Medical students are not considered Healthcare Professionals under the current guidelines and will be automatically classified as Non-Healthcare Professionals.

3. Industry sessions

Satellite Symposia presenting data on the development, research, or other issues related to prescription medicine is restricted to Healthcare Professionals and Non Members (INDUSTRY).

All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs.

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry Session.

The industry session organiser is responsible for compliance with the session.

E SYMPOSIUM



Exhibition and Industry Sessions





Exhibition

As an integral part of the EADV Symposium 2025, the exhibition area will take place in the Panorama hall, on level 1, and will serve as a central forum for industry to network and conduct exchange with the Healthcare Professionals.

The exhibition area will be open during the following hours:

Thursday 24 May 13:00 – 17:30
Friday 25 May 09:00 – 17:30
Saturday 26 May 09:00 – 12:00

Please visit our **EADV Symposium website** to view the exhibition floorplan.

Access to the exhibition area is limited exclusively to healthcare professionals (HCPs) and Non Members (INDUSTRY).

Industry sessions

Industry sessions programme

The industry sessions offer a unique opportunity to connect with key thought leaders, access to information on emerging science and innovative approaches to a wide range of current medical topics.

Three Satellite Symposia are organised between Thursday 22 May and Friday 23 May 2025.

Please visit our <u>EADV Symposium website</u> to view the industry sessions programme.

Satellite symposia programme and faculty in particular

The Industry Session organiser is solely responsible for keeping all its Industry Session activities compliant with all relevant laws and regulations. EADV is not involved with or has any control over the content, quality, organisation, operation, or scientific integrity of the activity and materials provided by the industries. EADV is not involved in the selection of speakers, moderators, and other faculty.

Access to satellite symposia

As a multidisciplinary audience will be attending the EADV Symposium 2025, please make sure to select the right category: Healthcare Professionals (HCPs) or Non-Healthcare Professionals (NON-HCPs), during the registration process.

Access to any Industry Sessions where data or research on prescription medicines is presented will be limited to Healthcare Professionals (HCPs) and Non Members (INDUSTRY).

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry Session.





Participating companies



UCB is a global biopharmaceutical company focused on creating valuable solutions that make improvements to the lives of people living with neurological and autoimmune conditions. At UCB, we believe that everyone deserves to live the best life that they can. UCB works closely and forges strong connections with patients, caregivers, healthcare professionals and other stakeholders who know the challenges of these diseases and the unmet needs. UCB is headquartered in Brussels, Belgium with approximately 8,700 people in 40 countries.



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.



Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.



L'Oréal Dermatological Beauty, a division of L'Oréal dedicated to developing scientifically advanced skincare solutions, and specifically our flagship brand La Roche-Posay, cordially invites you to an exclusive symposium dedicated to exploring the latest advancements in adult acne treatment.

This event offers a unique opportunity to connect with leading dermatologists and delve into the most effective and innovative therapeutic approaches for managing this prevalent and often distressing skin concern.

SILVER SPONSOR

L'Oréal Dermatological Beauty brands are developed in close collaboration with dermatologists, leveraging scientific expertise to create products that address a wide range of dermatological needs.

Our commitment to rigorous research and development ensures that our formulations are both effective and tolerable, providing optimal solutions for sensitive and acne-prone skin. This is an exceptional opportunity to gain valuable knowledge directly from experts in the field.



Driven by passion, we pioneer intelligent and user-centric skin imaging solutions that empower clinicians in medical and aesthetic dermatology worldwide. Together, we are your partners in advanced skin imaging and care.

FotoFinder is the global epitome of cutting-edge skin imaging technology for follow-up care and superior accuracy. We provide state-of-the-art solutions for Video Dermoscopy and Total Body Mapping, blending advanced imaging and artificial intelligence.

DermLite, known for its handheld dermoscopy devices, revolutionizes skin examinations with intuitive, high-quality, wearable imaging tools for quick assessments and new discoveries. With FotoFinder cloud integration, DermLite provides a flexible imaging solution.







SUPPORTER SPONSOR

Opatra Advanced Skincare Technologies brings together the latest technological leaps and scientific innovations to create potent skincare solutions and dynamic tools that are redefining the beauty industry. As a leading device manufacturer and wholesaler, Opatra recognizes that our remarkable success is a reflection of your happiness with our easy-to-use instruments that help to produce healthy, youthful, and glowing skin.



A.D.O. MEDICAL has as its primary objective the quality and satisfaction of the customer, with whom we favor the personal relationship before the commercial one.

SUPPORTER SPONSOR

In this perspective, the choice and quality of the product takes on a role of fundamental importance. Our aim is to simplify the life of Doctors and Operators in the Healthcare Sector by supplying highly reliable products.



SUPPORTER SPONSOR

Wisepress.com is Europe's leading conference bookseller. We have an wise press.co extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.



Universal Skin Technology produces mesotherapy cocktails, peelings and skincare products.

Our wide range of mesotherapy cocktails are sterilized by using microfiltration followed by a-septic filling. Also PDRN, CBD and Exosomes are offered within our sterile mesotherapy technology.

The company offers brands like Universal MesoExpert, Philoderm Premium Meso, Philoderm Peelings and Skincare.

SUPPORTER SPONSOR

Universal Skin Technology offers private label projects.



Griffin is a publishing house founded in 2006 that operates mainly in the professional field. Griffin's mission is to transfer to specialists useful information in daily operations, updating them on scientific, clinical and professional news through its cross-media communication means: the newspapers, scientific journals and editorial websites.

Under the historic brands Timeo and Acta Medica, Griffin's books division publishes specialist and university volumes for the training and updating of the doctor and his team.

SUPPORTER SPONSOR

Griffin is also a reliable and authoritative reference point for companies of the sector in the study and implementation of communication campaigns in the field of BtoB.



SUPPORTER SPONSOR

Developed in South Korea, Rejuran is a breakthrough injectable biostimulator that harnesses the regenerative power of highly purified polynucleotides (PN) derived from wild salmon DNA. It offers an advanced solution for skin rejuvenation, clinically proven to stimulate collagen production, accelerate tissue repair, and improve overall skin quality. Trusted by doctors worldwide for its safety, efficacy, and long-term effects, it is widely used to treat fine lines, acne scars, enlarged pores, and weakened skin barriers. Its strong antiinflammatory action also supports the healing of post-surgical scars by promoting dermal regeneration at the cellular level. As the first and only PNbased injectable in Europe with CE MDR certification, this innovation represents a new standard in regenerative aesthetics. It delivers visible, natural-looking results with minimal downtime and is a preferred choice among professionals committed to skin health and long-lasting rejuvenation.